High resolution deletion analysis of constitutional DNA from neurofibromatosis type 2 (NF2) patients using microarray-CGH.

Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder whose hallmark is bilateral vestibular schwannoma. It displays a pronounced clinical heterogeneity with mild to severe forms. The NF2 tumor suppressor (merlin/schwannomin) has been cloned and extensively analyzed for mutations in patients with different clinical variants of the disease. Correlation between the type of the NF2 gene mutation and the patient phenotype has been suggested to exist. However, several independent studies have shown that a fraction of NF2 patients with various phenotypes have constitutional deletions that partly or entirely remove one copy of the NF2 gene. The purpose of this study was to examine a 7 Mb interval in the vicinity of the NF2 gene in a large series of NF2 patients in order to determine the frequency and extent of deletions. A total of 116 NF2 patients were analyzed using high-resolution array-comparative genomic hybridization (CGH) on an array covering at least 90% of this region of 22q around the NF2 locus. Deletions, which remove one copy of the entire gene or are predicted to truncate the schwannomin protein, were detected in 8 severe, 10 moderate and 6 mild patients. This result does not support the correlation between the type of mutation affecting the NF2 gene and the disease phenotype. This work also demonstrates the general usefulness of the array-CGH methodology for rapid and comprehensive detection of small (down to 40 kb) heterozygous and/or homozygous deletions occurring in constitutional or tumor-derived DNA.

[1]  D. Evans,et al.  A genetic study of type 2 neurofibromatosis in the United Kingdom. I. Prevalence, mutation rate, fitness, and confirmation of maternal transmission effect on severity. , 1992, Journal of medical genetics.

[2]  W. Kuo,et al.  Quantitative mapping of amplicon structure by array CGH identifies CYP24 as a candidate oncogene , 2000, Nature Genetics.

[3]  S. Pulst,et al.  Neurofibromatosis 2 in the pediatric age group. , 1993, Neurosurgery.

[4]  D. Evans,et al.  A genetic study of type 2 neurofibromatosis in the United Kingdom. II. Guidelines for genetic counselling. , 1992, Journal of medical genetics.

[5]  D. Pinkel,et al.  Comparative Genomic Hybridization for Molecular Cytogenetic Analysis of Solid Tumors , 2022 .

[6]  L. Gaunt,et al.  A disease-associated germline deletion maps the type 2 neurofibromatosis (NF2) gene between the Ewing sarcoma region and the leukaemia inhibitory factor locus. , 1993, Human molecular genetics.

[7]  S. Pulst,et al.  A missense mutation in the neurofibromatosis 2 gene occurs in patients with mild and severe phenotypes , 1996, Neurology.

[8]  D. Evans,et al.  A clinical study of type 2 neurofibromatosis. , 1992, The Quarterly journal of medicine.

[9]  E. Blennow,et al.  Severe phenotype of neurofibromatosis type 2 in a patient with a 7.4‐MB constitutional deletion on chromosome 22: Possible localization of a neurofibromatosis type 2 modifier gene? , 1999, Genes, chromosomes & cancer.

[10]  Melanie E. Goward,et al.  The DNA sequence of human chromosome 22 , 1999, Nature.

[11]  R. Weksberg,et al.  Type of mutation in the neurofibromatosis type 2 gene (NF2) frequently determines severity of disease. , 1996, American journal of human genetics.

[12]  M. Kaiser-Kupfer,et al.  Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. , 1996, American journal of human genetics.

[13]  L. Kluwe,et al.  Mosaicism in sporadic neurofibromatosis 2 patients. , 1998, Human molecular genetics.

[14]  D. Evans,et al.  Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. , 1998, Journal of medical genetics.

[15]  M I Kaiser-Kupfer,et al.  Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. , 1994, American journal of medical genetics.

[16]  J. Dumanski,et al.  Presymptomatic diagnosis for neurofibromatosis 2 with chromosome 22 markers , 1993, Neurology.

[17]  W. Kuo,et al.  High resolution analysis of DNA copy number variation using comparative genomic hybridization to microarrays , 1998, Nature Genetics.

[18]  P. Dejong,et al.  Cloning of a novel, anonymous gene from a megabase-range YAC and cosmid contig in the neurofibromatosis type 2/meningioma region on human chromosome 22q12. , 1993, Human molecular genetics.

[19]  V. P. Collins,et al.  Characterization of a new member of the human beta-adaptin gene family from chromosome 22q12, a candidate meningioma gene. , 1994, Human molecular genetics.

[20]  B. Roe,et al.  Fine mapping of the constitutional translocation t(11;22)(q23;q11) , 2000, Human Genetics.

[21]  N. Carter,et al.  Fifty probands with extra structurally abnormal chromosomes characterized by fluorescence in situ hybridization. , 1995, American journal of medical genetics.

[22]  B. Korf,et al.  The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2. , 1997, Journal of the American Medical Association (JAMA).

[23]  D. Evans,et al.  Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. , 1998, American journal of human genetics.

[24]  S. Pulst,et al.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2 , 1993, Nature.

[25]  D. Evans,et al.  Misleading linkage results in an NF2 presymptomatic test owing to mosaicism. , 1997, Journal of medical genetics.

[26]  M. Sanson,et al.  Germline deletion in a neurofibromatosis type 2 kindred inactivates the NF2 gene and a candidate meningioma locus. , 1993, Human molecular genetics.

[27]  J. Haines,et al.  A novel moesin-, ezrin-, radixin-like gene is a candidate for the neurofibromatosis 2 tumor suppressor , 1993, Cell.

[28]  F. Sor,et al.  NF2 gene in neurofibromatosis type 2 patients. , 1998, Human molecular genetics.

[29]  R Eldridge,et al.  Neurofibromatosis 2 (bilateral acoustic neurofibromatosis). , 1988, The New England journal of medicine.

[30]  L. Kluwe,et al.  Identification of NF2 germ-line mutations and comparison with neurofibromatosis 2 phenotypes , 1996, Human Genetics.

[31]  E. Constant The diagnostic evaluation and multidisciplinary management of neurofibromatosis 1 and neurofibromatosis 2 , 1998 .

[32]  K. Hoang-Xuan,et al.  Screening for germ‐line mutations in the NF2 Gene , 1995, Genes, chromosomes & cancer.

[33]  J. Sambrook,et al.  Molecular Cloning: A Laboratory Manual , 2001 .

[34]  H. Döhner,et al.  Matrix‐based comparative genomic hybridization: Biochips to screen for genomic imbalances , 1997, Genes, chromosomes & cancer.